Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Summary

There is still no effective treatment for advanced mucosal melanoma at present. The efficacy of single-agent PD-1 inhibitors is less than 20%. It is urgent to explore regimens to improve the efficacy of PD-1 inhibitors in patients with advanced mucosal melanoma. This study is performed to explore the safety and efficacy of apatinib plus SHR-1210 in patients with advanced mucosa melanoma whose diseases progress after chemotherapy.

Timeline

Start

2019-06-04

Primary completion

2021-05-31

Completion

2022-05-31

Publications

• Zhang Y, Wang T, Lyu AQ, Zhang F, Li FH, Zhao LD, Wang ZB, Shang YM, Ma BZ, Dong XQ, Gao QL. Real-world study of SHR-1210 plus apatinib in the treatment of BRAF-negative mucosal melanoma: efficacy, safety and implications of precision medicine. Front Immunol. 2026 Apr 21;17:1755669. doi: 10.3389/fimmu.2026.1755669. eCollection 2026.

Drugs

Indications